glp-1 drugs review The New GLP-1 Receptor Agonists | New
Description
What Counts as a Generic GLP-1 Medication
doi:10.1016/j.ajo.2024.04.010 20
Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029
doi: 10.1016/j.neuropharm.2019.107748
Pharmacological management of polycystic ovary syndrome
